Insider Analysis From Sidley Austin LLP: Market Definition In Life Sciences Sector Under The Chinese Anti-Monopoly Law
This article was originally published in PharmAsia News
Executive Summary
By Chen Yang and Adrian Emch, Sidley Austin LLP, Beijin
You may also be interested in...
Pfizer Divests Its Swine Vaccine Business To Harbin Pharmaceutical Group In China As Condition Of $68 Billion Merger With Wyeth
SHANGHAI - Pfizer recently completed the divestment of its swine vaccine business in China to local company Harbin Bio-Vaccine, an animal health subsidiary of Harbin Pharmaceutical Group
Pfizer Divests Its Swine Vaccine Business To Harbin Pharmaceutical Group In China As Condition Of $68 Billion Merger With Wyeth
SHANGHAI - Pfizer recently completed the divestment of its swine vaccine business in China to local company Harbin Bio-Vaccine, an animal health subsidiary of Harbin Pharmaceutical Group
Competition And Antitrust Laws Sweeping Asia Create New Hurdles For MNCs
HONG KONG - The emergence and evolution of competition and antitrust regimes across Asia could create new hurdles for multinational pharmaceutical companies that control large swaths of a particular market or are looking to expand through mergers and acquisitions